Live financial news intelligence

Track market-moving stories before they get noisy

Real-time pulse of financial headlines curated from 5 premium feeds.

Latest market signal Czech Filtered by asset CRON
Coverage 167,092 Raw stories ingested 21,985 rewritten in CS_CZ • 4 to rewrite (last 2 days).
Agents 7 Live Pipeline agents
  • FMP Stock News Fetch every minute running now
  • FMP Forex News Fetch every 5 min 4m ago
  • CoinGecko News Fetch every 5 min 1m ago
  • FIO Stock News Fetch every 10 min 4m ago
  • Patria Stock News Fetch every 10 min 4m ago
  • Editorial rewrite Rewrite every minute running now
  • Asset sync Assets every 1 hour 43m ago

Latest coverage

Market News Feed

Scan headlines quickly, then expand any story for source context.

View
Language
Relevance
Clear
Details Date Content Source Relevance
2026-09-02 12:46 7d ago
2026-09-02 07:30 7d ago
Cronos rozšiřuje SOURZ by Spinach o jedlé produkty a vape
CRON Cronos Group
FMP Stock News 72
Original source text
 | Source: Cronos Group Inc.

TORONTO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos”), an innovative global cannabis company, is expanding its lineup of edible multipacks with the SOURZ by Spinach® Blue Raspberry Lemonade Fully Blasted multipack, featuring its first live resin gummy. This month the brand will also launch new flavors in its best-selling lineup of vape cartridges, Strawberry Banana and Sweet Citrus Punch.

The new SOURZ by Spinach® Blue Raspberry Lemonade Fully Blasted gummies will be exclusively sold in the SOURZ by Spinach® Fully Blasted 10-pack, Canada’s No. 1 edible multipack as of June 20261. The popular Blue Raspberry Lemonade flavor features the same bold dual-flavor and sweet-then-sour taste, while offering a full spectrum experience through 100% live resin infusion. The new additions to the Spinach® family of vapes bolster a popular flavor lineup with cannabinoid combinations that have made the brand the #1 vape brand in Canada, capturing 11% share of all vape sales in June 20261.

The newest additions to the lineups of SOURZ by Spinach® Fully Blasted edible multipacks and Spinach® vapes include:

10-Pack (10 x 10mg THC gummies):

SOURZ by Spinach® Blue Raspberry Lemonade Fully Blasted gummies, the brand’s first gummy infused with 100% live resin 1.2g and 1g Vapes:

Spinach® Strawberry Banana 1.2g vape (Indica) Featuring juicy strawberry and creamy banana flavor notes Spinach® Sweet Citrus Punch 1g liquid diamonds vape (Sativa) Infused with liquid diamonds and featuring sweet, tangy, and vibrant citrus flavor notes
“We’re thrilled to launch these exciting new flavors and products in our vape and edibles portfolios after a successful summer season for the Spinach® brand,” said Jeff Jacobson, Chief Growth Officer, Cronos. “Our leadership in these categories is driven by our focus on quality and innovation, and our ability to deliver new cannabis experiences that expand and differentiate our offerings, giving consumers more choice and reasons to choose Spinach®. We’re looking forward to announcing more exciting product launches in the fourth quarter of 2026 that we believe consumers will love.”

The new SOURZ by Spinach® Fully Blasted multipack and additions to the Spinach® vape portfolio are available now in Ontario, with wider national availability later this fall. To view the full lineup of Spinach® products, visit spinachcannabis.com.

1 HiFyre Retail Analytics – National Retail Dollar Sales by Brand in Canada – June 2026.

About Cronos
Cronos is a global cannabis company focused on scaling leading consumer goods products through research and development and innovation. With a passion to responsibly elevate the consumer experience, Cronos is building an iconic brand portfolio. Cronos’ diverse international brand portfolio includes Spinach®, PEACE NATURALS®, LIT™ and Lord Jones®. For more information about Cronos and its brands, please visit: thecronosgroup.com.

Forward-looking Statements  
This press release may contain information that may constitute “forward-looking information” or “forward-looking statements” within the meaning of applicable Canadian and U.S. securities laws and court decisions (collectively, “Forward-looking Statements”). All information contained herein that is not clearly historical in nature may constitute Forward-looking Statements. In some cases, Forward-looking Statements can be identified by the use of forward-looking terminology such as “may”, “will”, “expect”, “plan”, “anticipate”, “intend”, “potential”, “estimate”, “believe” or the negative of these terms, or other similar expressions intended to identify Forward-looking Statements. Some of the Forward-looking Statements contained in this press release include statements about the development and launch of new Spinach® products, including new flavors, formats and cannabinoid combinations; the timing and scope of the rollout and national availability of new SOURZ by Spinach® Fully Blasted and Spinach® vape products; the Company’s ability to develop new cannabis experiences that expand and differentiate its offerings; expectations regarding product innovation announcements in the fourth quarter of 2026; and the Company’s intention to build an international iconic brand portfolio by scaling leading consumer goods products through R&D and innovation. Forward-looking Statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive risks. Financial results, performance or achievements expressed or implied by those Forward-looking Statements and the Forward-looking Statements are not guarantees of future performance. A discussion of some of the material risks applicable to the Company can be found in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and the Company’s Quarterly Reports on Form 10-Q for the quarters ended March 31, 2026 and June 30, 2026, each of which has been filed on SEDAR+ and EDGAR and can be accessed at www.sedarplus.ca and www.sec.gov/edgar, respectively. Any Forward-looking Statement included in this press release is made as of the date of this press release and, except as required by law, Cronos disclaims any obligation to update or revise any Forward-looking Statement. Readers are cautioned not to put undue reliance on any Forward-looking Statement.

For further information, please contact:

 Media Relations Contact:  
Emily Whalen  
Communications  
Tel: (416) 504-0004  
[email protected]

 Investor Relations Contact: 
Harrison Aaron  
Investor Relations  
Tel: (416) 504-0004  
[email protected]
2026-08-06 15:29 1mo ago
2026-08-06 10:51 1mo ago
Cronos Group překonala odhady zisku na akcii i tržeb
CRON Cronos Group
FMP Stock News 78
Original source text
Cronos Group (CRON - Free Report) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to a loss of $0.1 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +200.00%. A quarter ago, it was expected that this cannabis company would post earnings of $0.01 per share when it actually produced earnings of $0.01, delivering no surprise.

Over the last four quarters, the company has surpassed consensus EPS estimates two times.

Cronos, which belongs to the Zacks Medical - Drugs industry, posted revenues of $53.01 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 24.11%. This compares to year-ago revenues of $33.46 million. The company has topped consensus revenue estimates three times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Cronos shares have added about 3.4% since the beginning of the year versus the S&P 500's gain of 12.8%.

What's Next for Cronos?While Cronos has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Cronos was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.01 on $55.37 million in revenues for the coming quarter and $0.07 on $203.6 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Drugs is currently in the bottom 39% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

One other stock from the same industry, ARS Pharmaceuticals, Inc. (SPRY - Free Report) , is yet to report results for the quarter ended June 2026. The results are expected to be released on August 13.

This company is expected to post quarterly loss of $0.55 per share in its upcoming report, which represents a year-over-year change of -19.6%. The consensus EPS estimate for the quarter has been revised 4.7% lower over the last 30 days to the current level.

ARS Pharmaceuticals, Inc.'s revenues are expected to be $31.89 million, up 102.9% from the year-ago quarter.
2026-06-30 21:27 2mo ago
2026-06-30 17:15 2mo ago
Cronos jmenoval ATB Cormark brokerem pro zpětné odkupy
CRON Cronos Group
FMP Stock News 72
Original source text
June 30, 2026 17:15 ET  | Source: Cronos Group Inc.

TORONTO, June 30, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (“Cronos” or the “Company”) (NASDAQ: CRON) (TSX: CRON), an innovative global cannabis company, announced today that it has appointed ATB Capital Markets Corp. (“ATB Cormark”) to act as its broker in connection with share repurchases over the facilities of the TSX or other alternative Canadian trading systems, in place of Virtu Canada Corp., under its previously announced share repurchase program.

About Cronos

Cronos is a global cannabis company focused on scaling leading consumer goods products through research and development and innovation. With a passion to responsibly elevate the consumer experience, Cronos is building an iconic brand portfolio. Cronos’ diverse international brand portfolio includes Spinach®, PEACE NATURALS®, LIT™ and Lord Jones®. For more information about Cronos and its brands, please visit: thecronosgroup.com.

Forward-Looking Information

This press release may contain information that may constitute “forward-looking information” or “forward-looking statements” within the meaning of applicable Canadian and U.S. securities laws and court decisions (collectively, “Forward-looking Statements”). All information contained herein that is not clearly historical in nature may constitute Forward-looking Statements. In some cases, Forward-looking Statements can be identified by the use of forward-looking terminology such as “may”, “will”, “expect”, “plan”, “anticipate”, “intend”, “potential”, “estimate”, “believe” or the negative of these terms, or other similar expressions intended to identify Forward-looking Statements. The forward-looking information in this news release includes, but is not limited to, statements related to the Company’s share repurchases over the facilities of the TSX and its share repurchase program. Forward-looking Statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive risks. Financial results, performance or achievements expressed or implied by those Forward-looking Statements and the Forward-looking Statements are not guarantees of future performance. A discussion of some of the material risks applicable to the Company can be found in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and the Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, each of which has been filed on SEDAR+ and EDGAR and can be accessed at www.sedarplus.ca and www.sec.gov/edgar, respectively. Any Forward-looking Statement included in this press release is made as of the date of this press release and, except as required by law, Cronos disclaims any obligation to update or revise any Forward-looking Statement. Readers are cautioned not to put undue reliance on any Forward-looking Statement.

For further information, please contact:
Harrison Aaron
Investor Relations
Tel: (416) 504-0004
[email protected]